Diabetes & Metabolic Syndrome Clinical Research & Reviews, Год журнала: 2020, Номер 15(1), С. 149 - 157
Опубликована: Дек. 15, 2020
Язык: Английский
Diabetes & Metabolic Syndrome Clinical Research & Reviews, Год журнала: 2020, Номер 15(1), С. 149 - 157
Опубликована: Дек. 15, 2020
Язык: Английский
Metabolism, Год журнала: 2021, Номер 121, С. 154814 - 154814
Опубликована: Июнь 11, 2021
Язык: Английский
Процитировано
88Annual Review of Medicine, Год журнала: 2021, Номер 73(1), С. 129 - 147
Опубликована: Авг. 11, 2021
The prevalence of diabetes in people with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has varied worldwide. Most the available evidence suggests a significant increase severity and mortality COVID-19 either type 1 (T1DM) or 2 mellitus (T2DM), especially association poor glycemic control. While new-onset hyperglycemia (both T1DM T2DM) have been increasingly recognized context associated worse outcome, no conclusive yet direct tropism SARS-CoV-2 on β cells pancreatic islets. all approved oral antidiabetic agents appear to be safe T2DM having COVID-19, data are indicate benefit any class these drugs, absence large randomized controlled trials.
Язык: Английский
Процитировано
84The Lancet Regional Health - Americas, Год журнала: 2022, Номер 13, С. 100303 - 100303
Опубликована: Июнь 24, 2022
Язык: Английский
Процитировано
63Frontiers in Cardiovascular Medicine, Год журнала: 2021, Номер 8
Опубликована: Фев. 17, 2021
Coronavirus disease 2019 (COVID-19) has become a worldwide pandemic responsible for millions of deaths around the world. Hypertension been identified as one most common comorbidities and risk factors severity adverse outcome in these patients. Recent investigations have raised question whether hypertension represents predictor COVID-19 patients independently other such diabetes, obesity, cardiovascular diseases, chronic kidney, liver, pulmonary diseases. However, impact newly diagnosed insufficiently investigated. The same is true relationship between blood pressure levels outcomes It seems that long discussion about angiotensin-converting enzyme inhibitors (ACEI) blockers angiotensin I receptors (ARB) on approaching an end because large number original studies meta-analyses discarded initial findings higher prevalence ACEI/ARB use with unfavorable outcomes. Nevertheless, there are many controversies COVID-19. aim this review article to provide clinical overview currently available evidence regarding predictive value hypertension, effect levels, previously known antihypertensive therapy
Язык: Английский
Процитировано
60Clinical Gastroenterology and Hepatology, Год журнала: 2022, Номер 20(7), С. 1553 - 1560.e78
Опубликована: Фев. 3, 2022
Язык: Английский
Процитировано
54Journal of Diabetes and its Complications, Год журнала: 2022, Номер 36(4), С. 108145 - 108145
Опубликована: Фев. 4, 2022
Язык: Английский
Процитировано
52Cell Reports, Год журнала: 2022, Номер 38(11), С. 110508 - 110508
Опубликована: Фев. 21, 2022
Concerns that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of disease 2019 (COVID-19), may cause new-onset diabetes persist in an evolving research landscape, and precise risk assessment is hampered by, at times, conflicting evidence. Here, leveraging comprehensive single-cell analyses vitro SARS-CoV-2-infected human pancreatic islets, we demonstrate productive strictly dependent on SARS-CoV-2 entry receptor ACE2 targets practically all cell types. Importantly, remains highly circumscribed largely non-cytopathic and, despite a high viral burden infected subsets, promotes only modest cellular perturbations inflammatory responses. Similar experimental outcomes are also observed after islet endemic coronaviruses. Thus, limits infection, even under conditions enhanced virus exposure, challenge proposition vivo targeting β cells by precipitates diabetes. Whether restricted damage immunological alterations accrued COVID-19 increase cumulative risk, however, to be evaluated.
Язык: Английский
Процитировано
48Scientific Reports, Год журнала: 2023, Номер 13(1)
Опубликована: Апрель 19, 2023
Abstract A COVID-19 patient often presents with multiple comorbidities and is associated adverse outcomes. comprehensive assessment of the prevalence in patients essential. This study aimed to assess comorbidities, severity mortality regard geographic region, age, gender smoking status COVID-19. systematic review multistage meta-analyses were reported using PRISMA guidelines. PubMed/MEDLINE, SCOPUS, Google Scholar EMBASE searched from January 2020 October 2022. Cross-sectional studies, cohort case series case–control studies on reporting among populations that published English included. The pooled various medical conditions was calculated based regional population size weights. Stratified analyses performed understand variations gender, region. total 190 comprising 105 million Statistical STATA software, version 16 MP (StataCorp, College Station, TX). Meta-analysis proportion obtain values comorbidities: hypertension (39%, 95% CI 36–42, n = 170 studies), obesity (27%, 25–30%, 169 diabetes 175), asthma (8%, 7–9%, 112). Moreover, hospitalization 35% (95% 29–41%, 61), intensive care admissions 17% 14–21, 106), 18% 16–21%, 145). highest Europe at 44% 39–47%, 68), 30% CI, 26–34, 79) 27% (95%CI, 24–30, 80) North America, 9% 8–11, 41). Obesity high ≥ 50 years (30%, 112) age group, Men (26%, 124) observational higher than (19% vs. 14%). Random effects meta-regression found a significant association between ( p < 0.001), 0.05), ICU admission 0.05) 0.001). Overall, global (39%) lower (8%), Hence, geographical regions respective chronic should accelerate regular booster dose vaccination, preferably those prevent disease novel SARS-CoV-2 variants concern (VOC).
Язык: Английский
Процитировано
43Metabolism, Год журнала: 2024, Номер 155, С. 155812 - 155812
Опубликована: Фев. 13, 2024
Язык: Английский
Процитировано
10Diabetes & Metabolic Syndrome Clinical Research & Reviews, Год журнала: 2021, Номер 15(5), С. 102271 - 102271
Опубликована: Сен. 1, 2021
Язык: Английский
Процитировано
47